By Greg Hazley
LipoScience is working with ICR for investor relations and financial communications on its $45m initial public offering Jan. 25.
Shares of the Raleigh-based diagnostic medical test maker, which were offered at $9, rose more than seven percent in its first morning of trading on Nasdaq.
LS makes an FDA-approved proprietary test for cholesterol to assess heart disease risk. The company said it will use $38.6M from the offering to hire sales and marketing personnel, among other expenditures.
ICR senior VP Bob Yedid handles the LS account.